BioCentury
ARTICLE | Company News

Vernalis, Britannia, Mylan Laboratories Inc. deal

November 7, 2005 8:00 AM UTC

VER acquired exclusive North American marketing rights to MYL's Apokyn apomorphine injection, which is marketed to treat "off" episodes associated with PD, for $23 million in cash. VER will complete certain Phase IV studies. The non-ergoline dopamine agonist has Orphan Drug status. It was launched in the U.S. in July 2004. ...